| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $768,726 | 4 | 100 |
| Huang Michael F. | Sr. VP of Clinical Development | 0 | $0 | 1 | $200,365 | $-200,365 |
| Manning Meredith | Chief Commercial Officer | 0 | $0 | 1 | $228,980 | $-228,980 |
| Hirano Patricia C | SEE REMARKS | 0 | $0 | 2 | $339,381 | $-339,381 |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Over the last 12 months, insiders at Soleno Therapeutics, Inc. have bought $0 and sold $768,726 worth of Soleno Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Soleno Therapeutics, Inc. have bought $14.93M and sold $66.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 250,000 shares for transaction amount of $5M was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2023‑09‑28.
| 2026-03-27 | Sale | Manning Meredith | Chief Commercial Officer | 7,522 0.0142% | $30.44 | $228,980 | +74.04% | |
| 2026-03-27 | Sale | Huang Michael F. | Sr. VP of Clinical Development | 6,582 0.0124% | $30.44 | $200,365 | +74.04% | |
| 2025-07-01 | Sale | Hirano Patricia C | SEE REMARKS | 3,830 0.0076% | $82.76 | $316,971 | -38.46% | |
| 2025-06-24 | Sale | Hirano Patricia C | SEE REMARKS | 266 0.0005% | $84.25 | $22,411 | -39.19% | |
| 2025-04-01 | Sale | Hirano Patricia C | SEE REMARKS | 3,782 0.0085% | $70.11 | $265,156 | -5.98% | |
| 2025-03-28 | Sale | Vivo Opportunity, LLC | 10 percent owner | 333,557 0.7133% | $70.60 | $23.55M | -10.08% | |
| 2025-03-28 | Sale | Hirano Patricia C | SEE REMARKS | 27,662 0.0581% | $69.40 | $1.92M | -10.08% | |
| 2025-03-28 | Sale | Pauls Matthew | director | 5,937 0.0129% | $71.55 | $424,797 | -10.08% | |
| 2025-03-27 | Sale | Vivo Opportunity, LLC | 10 percent owner | 1.1M 2.4133% | $67.80 | $74.58M | -3.61% | |
| 2025-03-27 | Sale | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | 699,095 1.5297% | $67.62 | $47.27M | -3.61% | |
| 2025-03-27 | Sale | Mackaness James H | CHIEF FINANCIAL OFFICER | 90,622 0.2036% | $69.44 | $6.29M | -3.61% | |
| 2025-03-27 | Sale | Hirano Patricia C | SEE REMARKS | 128,653 0.2844% | $68.32 | $8.79M | -3.61% | |
| 2025-03-27 | Sale | Manning Meredith | Chief Commercial Officer | 45,249 0.0985% | $67.28 | $3.04M | -3.61% | |
| 2025-03-27 | Sale | Huang Michael F. | Sr. VP of Clinical Development | 14,583 0.0328% | $69.51 | $1.01M | -3.61% | |
| 2025-03-27 | Sale | Yen Kristen | SEE REMARKS | 95,500 0.2063% | $66.77 | $6.38M | -3.61% | |
| 2025-03-26 | Sale | Vivo Opportunity, LLC | 10 percent owner | 400,000 1.1721% | $65.80 | $26.32M | +33.65% | |
| 2025-01-03 | Sale | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | 10,154 0.0235% | $46.18 | $468,875 | +40.92% | |
| 2025-01-03 | Sale | Mackaness James H | CHIEF FINANCIAL OFFICER | 3,791 0.0088% | $46.18 | $175,055 | +40.92% | |
| 2025-01-03 | Sale | Hirano Patricia C | SEE REMARKS | 1,459 0.0034% | $46.18 | $67,371 | +40.92% | |
| 2025-01-03 | Sale | Yen Kristen | SEE REMARKS | 2,340 0.0054% | $46.18 | $108,053 | +40.92% |
| Manning Meredith | Chief Commercial Officer | 64507 0.1247% | $3.39M | 0 | 2 | |
| Huang Michael F. | Sr. VP of Clinical Development | 39823 0.077% | $2.09M | 0 | 2 | |
| Hirano Patricia C | SEE REMARKS | 13206 0.0255% | $694,239.42 | 0 | 20 | |
| Abingworth LLP | 10 percent owner | 18022602 34.8477% | $947.45M | 3 | 0 | +8.21% |
| Sinclair Andrew | 18022602 34.8477% | $947.45M | 4 | 0 | +27.93% | |
| Vivo Opportunity, LLC | 10 percent owner | 4458294 8.6204% | $234.37M | 0 | 8 | |
| ENGLEMAN EDGAR | 4033540 7.7991% | $212.04M | 2 | 0 | ||
| Vivo Ventures V, LLC | 10 percent owner | 3633805 7.0262% | $191.03M | 2 | 18 | |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 3074542 5.9448% | $161.63M | 15 | 0 | +19.53% |
| MARIO ERNEST | 930000 1.7982% | $48.89M | 10 | 0 | ||
| FEINBERG LARRY N | 10 percent owner | 655000 1.2665% | $34.43M | 5 | 2 | +19.97% |
| Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | 577076 1.1158% | $30.34M | 4 | 16 | |
| Mackaness James H | CHIEF FINANCIAL OFFICER | 105176 0.2034% | $5.53M | 3 | 14 | <0.0001% |
| ENGELSEN STEINAR J | director | 80960 0.1565% | $4.26M | 3 | 0 | |
| Harris William G | director | 66271 0.1281% | $3.48M | 0 | 1 | |
| O'Toole David D | See Remarks | 44750 0.0865% | $2.35M | 7 | 0 | |
| TP MANAGEMENT VII LLC | 10 percent owner | 36823 0.0712% | $1.94M | 1 | 3 | |
| SCHULER JACK W | 10 percent owner | 36595 0.0708% | $1.92M | 34 | 79 | +5.14% |
| Yen Kristen | SEE REMARKS | 28143 0.0544% | $1.48M | 0 | 16 | |
| Melincoff Gwen A | director | 10000 0.0193% | $525,700.00 | 1 | 0 | +35.53% |
| Pauls Matthew | director | 6500 0.0126% | $341,705.00 | 0 | 1 | |
| BIOASIA MANGEMENT LLC | 10 percent owner | 0 0% | $0 | 0 | 2 |
$52,263,649 | 70 | 1.18% | $2.54B | |
$11,588,217 | 69 | 42.07% | $3.18B | |
$47,419,530 | 58 | 17.20% | $2.28B | |
$586,486,795 | 47 | 4.28% | $2.39B | |
$148,770,544 | 34 | 80.63% | $3.1B | |
$1,603,489 | 30 | 98.90% | $2.25B | |
Soleno Therapeutics, Inc. (SLNO) | $62,927,079 | 29 | 14.02% | $2.72B |
$137,061,250 | 16 | 23.01% | $3.05B | |
$18,336,420 | 12 | 24.03% | $2.94B | |
$1,248,715 | 10 | 5.66% | $2.7B | |
$45,445,266 | 9 | -24.96% | $2.83B | |
$32,575,266 | 8 | 37.03% | $3.06B | |
$4,623,072 | 7 | 11.07% | $2.43B | |
$91,589,325 | 7 | -6.97% | $3.3B | |
$666,380 | 5 | -16.60% | $2.57B | |
$3,200,000 | 5 | -11.36% | $2.77B | |
$1,407,368 | 5 | 31.21% | $2.45B | |
$24,000,085 | 4 | 33.26% | $2.68B | |
$17,235 | 1 | -51.12% | $2.98B |
| Increased Positions | 169 | +66.8% | 14M | +21.53% |
| Decreased Positions | 118 | -46.64% | 14M | -22.01% |
| New Positions | 63 | New | 4M | New |
| Sold Out Positions | 52 | Sold Out | 7M | Sold Out |
| Total Postitions | 304 | +20.16% | 65M | -0.49% |
| Fmr Llc | $377,345.00 | 14.81% | 8M | +5M | +139.66% | 2025-09-30 |
| Janus Henderson Group Plc | $285,678.00 | 11.22% | 6.06M | +748,330 | +14.1% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $184,100.00 | 7.23% | 3.9M | +441,424 | +12.75% | 2025-09-30 |
| Blackrock, Inc. | $164,730.00 | 6.47% | 3.49M | +647,505 | +22.76% | 2025-09-30 |
| Vanguard Group Inc | $132,413.00 | 5.2% | 2.81M | +319,317 | +12.84% | 2025-09-30 |
| Avoro Capital Advisors Llc | $121,594.00 | 4.77% | 2.58M | +527,777 | +25.75% | 2025-09-30 |
| Wellington Management Group Llp | $109,062.00 | 4.28% | 2.31M | +2M | +272.3% | 2025-09-30 |
| Vivo Capital, Llc | $107,463.00 | 4.22% | 2.28M | -2M | -42.45% | 2025-09-30 |
| State Street Corp | $102,502.00 | 4.02% | 2.17M | +768,053 | +54.67% | 2025-09-30 |
| Invesco Ltd. | $70,780.00 | 2.78% | 1.5M | +854,551 | +132.29% | 2025-09-30 |